Parizad Torabi-Parizi, M.D.

Investigator

Critical Care Medicine Department

NIH Clinical Center

View Site

Building 10, Room 2C145
10 Center Drive
Bethesda, MD 20892

301-496-9320

torabiparizip@cc.nih.gov

Research Topics

Dr. Parizad Torabi-Parizi is interested in understanding mechanisms of lung injury secondary to pulmonary infections by elucidating the nature and extent of the host's immune response.

Honors and Awards

  • Clinical Center CEO Award, 2018
  • Clinical Center CEO Award, 2017
  • Clinical Center Director's Award, 2015
  • NIH Director's Award, 2015
  • Clinical Center Director's Award, 2014
  • NIH Director's Award, 2012
  • NIAID Merit Award, 2011

Biography

Dr. Torabi-Parizi earned her undergraduate degree and degree in Medicine from Emory University. She completed her internship and residency training in Internal Medicine at the Johns Hopkins Hospital Osler Training Program.

Dr. Torabi-Parizi completed her fellowship training in Critical Care Medicine at the NIH and was subsequently appointed as Staff Clinician in the Critical Care Medicine Department at the NIH in 2011. She became an Assistant Clinical Investigator in the Critical Care Medicine Department in 2013 and is now a Tenure-Track Investigator. She also chairs the Clinical Center CPR committee.

She has had a long-standing interest in innate immune cell and effector T cell behavior in peripheral tissues, mechanisms regulating this behavior, and possible interventions that might modulate effector responses to improve host outcomes, in the context of critical illness.

Selected Publications

  2. Busch LM, Sun J, Cui X, Eichacker PQ, Torabi-Parizi P. Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis. Intensive Care Med Exp. 2020;8(1):7.
  3. Busch LM, Sun J, Eichacker PQ, Torabi-Parizi P. Inhibitory Immune Checkpoint Molecule Expression in Clinical Sepsis Studies: A Systematic Review. Crit Care Med. 2020;48(9):1365-1374.
  4. Curran CS, Bolig T, Torabi-Parizi P. Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection. Am J Respir Crit Care Med. 2018;197(6):708-727.
  5. Curran CS, Busch LM, Li Y, Xizhong C, Sun J, Eichacker PQ, Torabi-Parizi P. Anti-PD-L1 therapy does not improve survival in a murine model of lethal Staphyloccocus aureus pneumonia. J Infect Dis. 2021.

Related Scientific Focus Areas

This page was last updated on Thursday, September 2, 2021